Zobrazeno 1 - 10
of 31
pro vyhledávání: '"William D. Tap"'
Autor:
Philippe A. Cassier, Gerard J. Oakley, Christophe Massard, Danni Yu, Bailey Anderson, Shubham Pant, William D. Tap, Analia Azaro, Jaime R. Merchan, Eunice Yuen, Antoine Italiano, Karim A. Benhadji
Publikováno v:
Investigational New Drugs. 39:1089-1098
Notch signaling plays an important role in development and tissue homeostasis. Deregulation of Notch signaling has been implicated in multiple malignancies. Crenigacestat (LY3039478), a potent Notch inhibitor, decreases Notch signaling and its downst
Autor:
Dale Shuster, Hans Gelderblom, Hamim Zahir, Michiel A. J. van de Sande, William D. Tap, Daniel Polhamus, Jonathan French, John H. Healey, Silvia Stacchiotti, Ophelia Yin, Jonathan Greenberg, Xiaoning Wang, Andrew J. Wagner
Publikováno v:
CPT: Pharmacometrics and Systems Pharmacology, 10(11), 1422-1432. WILEY
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1422-1432 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1422-1432 (2021)
CPT: Pharmacometrics & Systems Pharmacology
This analysis was conducted to assess exposure–response relationships for efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed categorically by overall response rate (ORR) with Response Evaluatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fde6cee7310aa36880d826b65e2155e
https://hdl.handle.net/1887/3274139
https://hdl.handle.net/1887/3274139
Autor:
Denise K. Reinke, Matthew B. Schabath, Rikesh J Makanji, Michal R. Tomaszewski, Robert A. Gatenby, Damon R. Reed, Robert J. Gillies, Alberto Garcia, Shuxuan Fan, Young-Chul Kim, William D. Tap, Jin Qi
PurposeSuccess of new cancer therapies relies strongly on effective selection of the target patient populations. We hypothesize that computational analysis of imaging data can be used for patient enrichment in clinical trials and hence aimed to estab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e8ceaa64eb7430815fdd0b0c415b526
https://doi.org/10.1101/2021.01.18.21249895
https://doi.org/10.1101/2021.01.18.21249895
Autor:
Olivier Mir, Shreyaskumar Patel, Victor M. Villalobos, Kate J. Newberry, Suzanne George, Maria Roche, Peter Hohenberger, Mehdi Brahmi, Lin Shen, Robin L. Jones, Yongjian Zhou, Kevin He, Jonathan C. Trent, Maria Abbondanza Pantaleo, Sebastian Bauer, Margaret von Mehren, Piotr Rutkowski, Michael Heinrich, Paggy Hew, Yoon-Koo Kang, Patrick Schöffski, William D. Tap
PURPOSE Primary or secondary mutations in KIT or platelet-derived growth factor receptor alpha ( PDGFRA) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors (GISTs). Avapritinib selectively and potently inhibits KIT- and PDGFRA-mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ffc30c9ccb2043b337ed38169a25abc
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85117739966
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85117739966
Autor:
Michiel A. J. van de Sande, Sebastian Bauer, Hideo A. Baba, Andrew J. Wagner, John H. Healey, Mihaela Druta, Qiang Wang, Dale Shuster, James H. Lewis, Antonio López Pousa, Silvia Stacchiotti, Chia-Chi Lin, Hans Gelderblom, William D. Tap, Youngsook Choi
Publikováno v:
The Oncologist
The Oncologist, 26(5), e863-e873. WILEY
ONCOLOGIST
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
The Oncologist, 26(5), e863-e873. WILEY
ONCOLOGIST
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib. Materials, and Methods Hepatic adverse react
Autor:
Evan Rosenbaum, Sandra P. D'Angelo, Ciara Marie Kelly, Sujana Movva, Chloe Mcfadyen, William D. Tap, Ping Chi, Mercedes M. Condy, Samuel Singer, Mrinal M. Gounder, C. R. Antonescu, Mark A. Dickson, Sinchun Hwang, Li-Xuan Qin, Mary Louise Keohan, Travis Adamson
Publikováno v:
The Oncologist
Lessons Learned The combination of pexidartinib and binimetinib was safe and tolerable and demonstrated encouraging signs of efficacy in two patients with advanced gastrointestinal stromal tumor (GIST) refractory to tyrosine kinase inhibitors (TKIs).
Autor:
Y-K Kang, Suzanne George, A. Doyle, Robin L. Jones, N. Picazio, Michael Heinrich, Maria Roche, William D. Tap, Olivier Mir, T. Zhou, Sebastian Bauer
Poster-Abstract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30a43cb98d261d850c2a8b2db9f34f04
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85079739312
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85079739312
Autor:
Zsuzsanna Papai, Eugenie Younger, Denise K. Reinke, Karla V. Ballman, William D. Tap, Yao Lu, Robin L. Jones, Steven Attia, Brian A. Van Tine, Patrick Schöffski
Publikováno v:
Journal of Geriatric Oncology, 11, 3, pp. 463-469
Journal of Geriatric Oncology, 11, 463-469
Journal of Geriatric Oncology, 11, 463-469
BACKGROUND: More than half of patients with soft tissue sarcoma (STS) are aged ≥65 years (older), however contemporary data on the efficacy/safety of anthracycline chemotherapy in older patients with STS are lacking. METHODS: SARC021 randomized pat
Autor:
Gary A. Ulaner, Haley Phelan, Samuel Singer, William D. Tap, Li-Xuan Qin, Mary Louise Keohan, Matthew Biniakewitz, Moriah Martindale, Sandra P. D'Angelo, Aimee M. Crago, Ciara Marie Kelly, Sam S. Yoon, Mark A. Dickson, Mrinal M. Gounder, Sinchun Hwang, Benjamin A. Nacev, Ping Chi, Mercedes M. Condy, Sujana Movva, Cristina R. Antonescu
Publikováno v:
Journal of Clinical Oncology. 38:11508-11508
11508 Background: ETV1 and KIT are lineage-specific master transcriptional and signaling survival factors in GIST. In preclinical models, dual lineage targeting of ETV1 by MEK inhibition with BINI and KIT by imatinib are synergistic in suppressing GI
CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::971f1ba0ec78608936e5d52ee31dac78
https://europepmc.org/articles/PMC6039233/
https://europepmc.org/articles/PMC6039233/